Integra LifeSciences Holdings Corporation (IART) — Financial statements
Income statement, balance sheet, and cash flow for Integra LifeSciences Holdings Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,635↑1.5% | 1,611↑4.5% | 1,542↓1.0% | 1,558↑1.0% | 1,542 | |
| Cost of Revenue | 790↑8.4% | 728↑10.9% | 657↑11.8% | 587↓1.7% | 598 | |
| Gross Profit | 845↓4.2% | 882↓0.3% | 885↓8.8% | 970↑2.7% | 945 | |
| Operating Expenses | ||||||
| R&D Expenses | 99↓14.2% | 115↑10.7% | 104↑3.0% | 101↑8.8% | 93 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 700↓2.4% | 717↑9.2% | 657↑6.5% | 616↓3.3% | 637 | |
| Other Expenses | -22↓202.2% | 21↑72.0% | 12↓10.8% | 14↓17.9% | 17 | |
| Operating Expenses | 777↓9.0% | 854↑10.4% | 773↑5.7% | 731↓2.1% | 747 | |
| Total Costs & Expenses | 1,567↓1.0% | 1,582↑10.6% | 1,430↑8.4% | 1,319↓2.0% | 1,345 | |
| Operating Results | ||||||
| Operating Income | 68↑140.5% | 28↓74.5% | 112↓53.3% | 239↑21.1% | 197 | |
| Depreciation & Amortization | 151↑7.5% | 141↑13.8% | 124↑2.0% | 121↓2.1% | 124 | |
| EBITDA | -326↓268.8% | 193↓24.5% | 256↓33.4% | 385↑5.0% | 366 | |
| EBIT | -477↓1010.9% | 52↓60.4% | 132↓49.7% | 263↑8.6% | 243 | |
| Interest & Other Income | ||||||
| Net Interest Income | -68↓34.0% | -51↓48.0% | -34↑9.3% | -38↑13.7% | -44 | |
| Interest Income | 18↓7.8% | 20↑16.5% | 17↑44.3% | 12↑76.9% | 7 | |
| Interest Expense | 86↑22.1% | 71↑37.5% | 51↑3.6% | 50↓1.6% | 50 | |
| Non-Operating Income | 546↑2374.7% | -24↓14.6% | -21↑14.8% | -25↑45.9% | -45 | |
| Other Income / Expenses | -632↓1254.4% | -47↓53.2% | -30↓21.7% | -25↓243.4% | 17 | |
| Income Before Tax | -564↓2989.9% | -18↓122.5% | 81↓62.1% | 214↓0.4% | 215 | |
| Income Tax Expense | -47↓316.4% | -11↓184.7% | 13↓60.0% | 33↓26.9% | 46 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -516↓7337.7% | -7↓110.3% | 68↓62.5% | 181↑6.8% | 169 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -516↓7337.7% | -7↓110.3% | 68↓62.5% | 181↑6.8% | 169 | |
| Bottom-Line Net Income | -516↓7337.7% | -7↓110.3% | 68↓62.5% | 181↑6.8% | 169 | |
| EPS (Basic) | -6.73↓7361.2% | -0.09↓110.4% | 0.87↓60.1% | 2.18↑9.0% | 2.00 | |
| EPS (Diluted) | -6.73↓7361.2% | -0.09↓110.7% | 0.84↓61.1% | 2.16↑9.1% | 1.98 | |
| Weighted Average Shares | 77↓0.3% | 77↓1.5% | 78↓5.8% | 83↓2.0% | 85 | |
| Weighted Average Diluted Shares | 77↓0.3% | 77↓4.1% | 80↓3.8% | 84↓2.3% | 85 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.